Loading
A phase 3 trial of Selpercatinib in non-small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT04819100 by Eli Lilly and Company, with 152 participants enrolled, started 2021-12-20 and due to reach its primary completion in 2026-01-12. Interventions recorded: Selpercatinib and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Resectable stage I to III non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors and the tag pipeline.
Shares Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/